News

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue ... Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.

An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.

The healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways.

LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U. Prices for the lowest doses of both Novo's oral Wegovy and Lilly's Foundayo tend to be lower than for their injected obesity ‌medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions.

The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Elon Musk could pass an unthinkable wealth threshold, becoming the world’s first trillionaire, depending on investors’ excitement for SpaceX shares when it goes public. If the company surpasses a valuation of about $1.7 trillion, then Musk’s slightly more than 40% stake, combined with his Tesla shares, would make him the first man with a net worth eclipsing 13 figures. The calculation omits restricted shares that SpaceX has granted to Musk, but which haven’t been earned, though it includes options he could exercise shortly.

Novo Nordisk-linked pharmaceutical strength helped Denmark post a fourth straight quarter of economic expansion.

Eli Lilly (NYSE:LLY) has partnered with Collaborative Drug Discovery to make its AI drug discovery platform, Lilly TuneLab, more widely accessible. Biotech companies using CDD Vault can now access Lilly's predictive AI and machine learning tools directly in their existing research workflows. The agreement is designed to support broader data sharing and collaboration across drug discovery partners. Eli Lilly enters this partnership with strong recent stock performance and a high share price...

These stocks have declined this year, while the consensus estimates for the companies’ earnings per share have soared.

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic ‌to make its Claude AI model ‌available to over 30,000 employees in an effort to ​accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its ‌use in research, ⁠drug development, manufacturing and other commercial and medical affairs. • Agentic ​AI, which ​requires little human intervention, could increase clinical development productivity by about 35% to 45% ​over the ‌next five years, consultancy McKinsey said last ​year.

(Bloomberg) -- The way Unilever Plc Chief Executive Officer Fernando Fernandez starts every meeting at the consumer products maker says a lot about the mindset of corporate bosses who fear their companies have lost their edge.Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Thre

On a recent episode of Earn Your Leisure titled “The #1 Investing Mistake Keeping You Broke,” co-host E delivered a blunt diagnosis for retail investors: stop trading the stocks you should be holding. “The ones that are leading now will lead,” he said, warning that top companies could compound 4,000% or 5,000% over five or ... “4,000% or 5,000% Over Five or Six Years”: Why Patient Investors in NVDA, AMD, and LLY Are Winning

The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway. Trump signed his “most favored nation” drug pricing executive order last May, tying what Medicare pays to lower prices in other ... Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

Dell stock received two price-target hikes after the company detailed its strategy to capitalize on the AI megatrend.

The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%. Over five years, FHLC has returned 15% against about 80% for the S&P 500. If you bought FHLC for cheap sector diversification, fine. If you bought it expecting healthcare to keep pace with ... If You Hold This Healthcare ETF, You’re Losing Big

Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.

This dark horse in the weight loss drug race is worth keeping on your watch list.

The company is riding an incredible tailwind.

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He

U.S. Supreme Court declined to hear Eli Lilly's appeal in a major whistleblower case tied to Medicaid rebates. The decision leaves in place a significant judgment related to allegations the company underpaid rebates to the government program. The ruling highlights legal and compliance risks around how pharmaceutical companies interact with U.S. government healthcare programs. Eli Lilly (NYSE:LLY) faces this legal setback with its stock at $1,004.92, after a gain of 3.9% over the past week...

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State St

Eli Lilly (NYSE:LLY) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here’s what you should actually be watching. The ... Three Biotechs That Are Top Takeover Targets

Strong drug sales continue to drive growth, but expectations are climbing

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.

Drugmaker sees international markets as next test for obesity pill demand.